Related Experiment Videos
Insights
Prosthetic valve endocarditis (PVE) affected 3.6% of patients after valve replacement. Key risk factors included prior native valve endocarditis and mechanical prostheses, with most deaths occurring within three months.
Area of Science:
- Cardiology
- Infectious Diseases
- Surgical Outcomes
Background:
- Prosthetic valve endocarditis (PVE) is a significant complication following valve replacement surgery.
- Understanding risk factors and temporal patterns of PVE is crucial for patient management.
Purpose of the Study:
- To identify risk factors associated with the development of PVE in patients who underwent valve replacement.
- To describe the temporal occurrence and clinical characteristics of PVE.
Main Methods:
- Retrospective analysis of 1465 consecutive in-hospital survivors of valve replacement between 1975 and 1979.
- Identification of patients who developed PVE and analysis of associated risk factors and outcomes.
Main Results:
- Fifty-three patients (3.6%) developed PVE. Significant risk factors included prior native valve endocarditis, black race, mechanical prosthesis, male sex, and longer cardiopulmonary bypass time.
- The highest hazard for PVE occurred within 3 weeks post-surgery. Certain PVE subtypes had distinct temporal patterns.
- Mortality was high (64%), with most deaths occurring within 3 months of PVE diagnosis.
Conclusions:
- PVE is a serious complication with a high mortality rate.
- Early detection and intervention are critical, and enhanced preventive strategies are warranted.
- Risk stratification based on identified factors may improve patient outcomes.
Abstract:
Fifty-three (3.6%; actuarially 4.1% at 48 months) of 1465 consecutive in-hospital survivors of valve replacement from 1975 to July 1979 (aortic, mitral, or aortic and mitral, only one untraced) developed prosthetic valve endocarditis (PVE). Incremental risk factors for developing PVE were native valve endocarditis (p less than .0001), black race (p = .0001), mechanical prosthesis (vs bioprosthesis) (p = .005), male sex (p = .04), and longer cardiopulmonary bypass time (p = .09). In general, the hazard function for developing PVE was greatest at 3 weeks after valve replacement. Patients with native valve endocarditis had a tendency to develop PVE early after valve replacement, as did patients in whom mechanical prostheses were used. PVE associated with Staphylococcus epidermidis tended to appear within 6 months of valve replacement, whereas streptococcal PVE tended to appear later after valve replacement. PVE took an atypical form in some patients, but patients with possible PVE (n = 6) had the same findings as those with certain PVE (n = 47). In 11 patients bacteriologic confirmation of PVE was not obtained. The typical prosthetic and periprosthetic characteristics of PVE were present in 30 of the 40 cases in which observations were possible. PVE is a serious condition; 34 (64%) of our 53 patients died. Most deaths occurred within 3 months of the first evidence of PVE. Recovery of some patients is possible with appropriate medical and surgical treatment, but more intense preventive measures are indicated.